MA38555A1 - Dérivés de pyrrolo[2,3-d]pyrimidine en tant qu'agonistes du récepteur cb2 - Google Patents

Dérivés de pyrrolo[2,3-d]pyrimidine en tant qu'agonistes du récepteur cb2

Info

Publication number
MA38555A1
MA38555A1 MA38555A MA38555A MA38555A1 MA 38555 A1 MA38555 A1 MA 38555A1 MA 38555 A MA38555 A MA 38555A MA 38555 A MA38555 A MA 38555A MA 38555 A1 MA38555 A1 MA 38555A1
Authority
MA
Morocco
Prior art keywords
pyrrolo
receptor agonists
pyrimidine derivatives
formula
compound represented
Prior art date
Application number
MA38555A
Other languages
English (en)
Other versions
MA38555B1 (fr
Inventor
Uwe Grether
Atsushi Kimbara
Matthias Nettekoven
Stephan Roever
Mark Rogers-Evans
Tanja Schulz-Gasch
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA38555A1 publication Critical patent/MA38555A1/fr
Publication of MA38555B1 publication Critical patent/MA38555B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un composé représenté par la formule (i) dans laquelle a et r1 à r3 sont tels que définis dans la description et dans les revendications. Le composé représenté par la formule (i) peut être utilisé en tant que médicament
MA38555A 2013-05-02 2014-04-29 Dérivés de pyrrolo[2,3-d]pyrimidine en tant qu'agonistes du récepteur cb2 MA38555B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13166296 2013-05-02
PCT/EP2014/058648 WO2014177527A1 (fr) 2013-05-02 2014-04-29 Dérivés de pyrrolo[2,3-d]pyrimidine en tant qu'agonistes du récepteur cb2

Publications (2)

Publication Number Publication Date
MA38555A1 true MA38555A1 (fr) 2017-09-29
MA38555B1 MA38555B1 (fr) 2018-04-30

Family

ID=48190401

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38555A MA38555B1 (fr) 2013-05-02 2014-04-29 Dérivés de pyrrolo[2,3-d]pyrimidine en tant qu'agonistes du récepteur cb2

Country Status (34)

Country Link
US (1) US9580435B2 (fr)
EP (1) EP2991988B1 (fr)
JP (1) JP6454689B2 (fr)
KR (1) KR20160002857A (fr)
CN (1) CN105164133B (fr)
AR (1) AR096153A1 (fr)
AU (1) AU2014261546B2 (fr)
BR (1) BR112015027394A8 (fr)
CA (1) CA2907691A1 (fr)
CL (1) CL2015003196A1 (fr)
CR (1) CR20150555A (fr)
CY (1) CY1119114T1 (fr)
DK (1) DK2991988T3 (fr)
EA (1) EA028123B1 (fr)
ES (1) ES2635632T3 (fr)
HR (1) HRP20171099T1 (fr)
HU (1) HUE035333T2 (fr)
IL (1) IL242162B (fr)
LT (1) LT2991988T (fr)
MA (1) MA38555B1 (fr)
MX (1) MX373855B (fr)
MY (1) MY182237A (fr)
NZ (1) NZ712030A (fr)
PE (1) PE20160039A1 (fr)
PH (1) PH12015502409A1 (fr)
PL (1) PL2991988T3 (fr)
PT (1) PT2991988T (fr)
RS (1) RS56313B1 (fr)
SG (1) SG11201509029PA (fr)
SI (1) SI2991988T1 (fr)
TW (1) TWI680129B (fr)
UA (1) UA116801C2 (fr)
WO (1) WO2014177527A1 (fr)
ZA (1) ZA201507008B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3041843T3 (pl) 2013-09-06 2019-06-28 F. Hoffmann-La Roche Ag Pochodne triazolo[4,5-d]pirymidyny jako antagoniści receptora cb2
AU2015341811A1 (en) * 2014-11-07 2017-03-30 F. Hoffmann-La Roche Ag Triazolo[4,5-d]pyrimidines as agonists of the cannabinoid receptor 2
WO2017220544A1 (fr) 2016-06-23 2017-12-28 F. Hoffmann-La Roche Ag Nouveaux dérivés de [1,2,3]triazolo[4,5-d]pyrimidine
WO2017220516A1 (fr) 2016-06-23 2017-12-28 F. Hoffmann-La Roche Ag Dérivés de triazolo[4,5-d]pyrimidine
MA45442A (fr) 2016-06-23 2019-05-01 Hoffmann La Roche Dérivés de [1,2,3]triazolo[4,5-d]pyrimidine ayant une affinité pour le récepteur cannabinoïde de type 2
CN109311886B (zh) 2016-06-23 2021-11-09 豪夫迈·罗氏有限公司 [1,2,3]三唑并[4,5-d]嘧啶衍生物
JP2023541601A (ja) 2020-09-10 2023-10-03 プレシリックス・ナームローゼ・ベンノートシヤープ Ｆａｐに対する抗体フラグメント
WO2023203135A1 (fr) 2022-04-22 2023-10-26 Precirix N.V. Anticorps radiomarqué amélioré
AU2023264245A1 (en) 2022-05-02 2024-12-19 Precirix N.V. Pre-targeting

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001058869A2 (fr) 2000-02-11 2001-08-16 Bristol-Myers Squibb Company Modulateurs de recepteurs aux cannabinoides, leurs procedes de preparation et utilisations de modulateurs de recepteurs aux cannabinoides pour le traitement de maladies respiratoires et non respiratoires
EP1492784A4 (fr) 2002-03-28 2006-03-29 Merck & Co Inc 2,3-diphenyl-pyridines substituees
DE10219435A1 (de) 2002-05-02 2003-11-13 Bayer Cropscience Ag Substituierte Pyrazolo-pyrimidin-4-one
TWI270549B (en) * 2002-12-26 2007-01-11 Taisho Pharmaceutical Co Ltd Pyrrolopyrimidine and pyrrolopyridine derivatives substituted with cyclic amino group
AR051596A1 (es) 2004-10-26 2007-01-24 Irm Llc Compuestos heterociclicos condensados nitrogenados como inhibidores de la actividad del receptor canabinoide 1; composiciones farmaceuticas que los contienen y su empleo en la preparacion de medicamentos para el tratamiento de trastornos alimentarios
WO2007120454A1 (fr) * 2006-03-30 2007-10-25 Irm Llc Azolopyrimidines inhibitrices de l'activité du récepteur cannabinoïde 1
ES2395583T3 (es) * 2007-05-10 2013-02-13 Ge Healthcare Limited IMIDAZOL (1,2-A)PIRIDINAS y compuestos relacionados con actividad frente a los receptores cannabinoides CB2
US20090062253A1 (en) * 2007-08-31 2009-03-05 Kalypsys, Inc. Heterocyclodiazepine cannabinoid receptor modulators for treatment of disease
WO2009051705A1 (fr) 2007-10-18 2009-04-23 Merck & Co., Inc. 1,2,4-oxadiazoles substitués et leurs analogues comme modulateurs des récepteurs cb2, utiles dans le traitement de la douleur et de maladies respiratoires et non respiratoires
UA104010C2 (en) * 2008-12-18 2013-12-25 Эли Лилли Энд Компани Purine compounds
WO2010118367A2 (fr) 2009-04-10 2010-10-14 Progenics Pharmaceuticals, Inc. Pyrimidines antivirales
ES2426407T3 (es) * 2009-10-15 2013-10-23 Pfizer Inc. Compuestos de pirrolo[2,3-d]pirimidina
US9321727B2 (en) 2011-06-10 2016-04-26 Hoffmann-La Roche Inc. Pyridine derivatives as agonists of the CB2 receptor
UA111640C2 (uk) 2011-11-08 2016-05-25 Ф. Хоффманн-Ля Рош Аг ПОХІДНІ [1,2,3]ТРИАЗОЛО[4,5-d]ПІРИМІДИНУ ЯК АГОНІСТИ КАНАБІНОЇДНОГО РЕЦЕПТОРА 2
BR112014032996A2 (pt) 2012-07-04 2018-05-15 Hoffmann La Roche derivados de adamantil como agonistas do receptor de canabinoide 2
JP6426619B2 (ja) 2012-12-07 2018-11-21 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｃｂ２アゴニストとして有用なピリジン−２−アミド
HRP20180672T1 (hr) 2012-12-07 2018-06-01 F. Hoffmann - La Roche Ag Novi derivati piridina
SI2928882T1 (sl) 2012-12-07 2017-05-31 F. Hoffmann-La Roche Ag Pirazinski derivati kot agonisti receptorja CB2
HRP20171459T1 (hr) 2012-12-07 2017-11-03 F. Hoffmann - La Roche Ag Piridin-2-amidi korisni kao agonisti cb2
EA027935B1 (ru) 2013-03-07 2017-09-29 Ф. Хоффманн-Ля Рош Аг Новые производные пиразола
CN105209466B (zh) 2013-05-02 2018-05-18 豪夫迈·罗氏有限公司 作为cb2受体激动剂的嘌呤衍生物

Also Published As

Publication number Publication date
CN105164133A (zh) 2015-12-16
CR20150555A (es) 2015-11-20
KR20160002857A (ko) 2016-01-08
BR112015027394A8 (pt) 2018-01-30
JP6454689B2 (ja) 2019-01-16
JP2016517874A (ja) 2016-06-20
SG11201509029PA (en) 2015-12-30
MY182237A (en) 2021-01-18
MA38555B1 (fr) 2018-04-30
MX373855B (es) 2020-03-25
DK2991988T3 (en) 2017-08-21
ZA201507008B (en) 2017-08-30
PH12015502409B1 (en) 2016-02-22
SI2991988T1 (sl) 2017-09-29
PH12015502409A1 (en) 2016-02-22
RS56313B1 (sr) 2017-12-29
US20160046637A1 (en) 2016-02-18
CL2015003196A1 (es) 2016-06-03
EA201591939A1 (ru) 2016-03-31
AR096153A1 (es) 2015-12-09
ES2635632T3 (es) 2017-10-04
EA028123B1 (ru) 2017-10-31
IL242162B (en) 2019-06-30
AU2014261546B2 (en) 2018-01-18
TWI680129B (zh) 2019-12-21
EP2991988A1 (fr) 2016-03-09
TW201522343A (zh) 2015-06-16
LT2991988T (lt) 2017-08-10
BR112015027394A2 (pt) 2017-07-25
HK1213559A1 (zh) 2016-07-08
MX2015014081A (es) 2015-12-11
CY1119114T1 (el) 2018-02-14
NZ712030A (en) 2021-03-26
UA116801C2 (uk) 2018-05-10
WO2014177527A1 (fr) 2014-11-06
PT2991988T (pt) 2017-07-25
CN105164133B (zh) 2018-02-13
CA2907691A1 (fr) 2014-11-06
EP2991988B1 (fr) 2017-05-31
US9580435B2 (en) 2017-02-28
PL2991988T3 (pl) 2017-10-31
PE20160039A1 (es) 2016-01-28
HUE035333T2 (en) 2018-05-02
HRP20171099T1 (hr) 2017-10-06
AU2014261546A1 (en) 2015-09-24

Similar Documents

Publication Publication Date Title
MA38555B1 (fr) Dérivés de pyrrolo[2,3-d]pyrimidine en tant qu'agonistes du récepteur cb2
MA38403A1 (fr) Nouveaux dérivés de pyrazole modulateurs specifiques de cb2
MA38460A1 (fr) Dérivés de la purine en tant qu'agonistes du récepteur cb2
MA38404A1 (fr) Nouveaux dérivés de pyridine
MA38826B1 (fr) Nouveaux dérivés de triazolo[4,5-d]pyrimidine
MA38239A1 (fr) Nouveaux dérivés de pyridine
MA38218A1 (fr) Pyridine-2-amides utiles comme agonistes de cb2
MA45153A (fr) Dérivés de carbonucléosides substitués utiles en tant qu'agents anticancéreux
MA35663B1 (fr) Dérivés de [1, 2, 3]triazolo [4, 5 -d] pyrimidine comme agonistes des récepteurs aux cannabinoïdes 2
EA201490912A1 (ru) Производные [1,2,3]триазоло[4,5-d]пиримидина в качестве агонистов каннабиноидного рецептора 2
EP2970119A4 (fr) Nouveaux dérivés d'indole utiles en tant qu'agents antidiabétiques
MA34078B1 (fr) Derives d'arylethynyle
EP2900665A4 (fr) Dérivés triazolyle en tant qu'inhibiteurs de la syk
CL2018002811A1 (es) Derivados de aminotiazol útiles como agentes antivíricos.
EA201591008A1 (ru) Пиридин-2-амиды, пригодные в качестве агонистов каннабиноидного рецептора 2
MA43400B1 (fr) Dérivés de phényle en tant qu'agonistes du récepteur cannabinoïde 2
MA40281B1 (fr) Composés de pyrazole et leur utilisation en tant qu' agents de blocage des canaux calciques de type t
EP2875024A4 (fr) Dérivés de pyrimidinone amido-substituée pouvant être utilisés en vue du traitement de l'infection par le vih
EA201591815A1 (ru) Бицикло [2.2.2] кислоты - модуляторы gpr120
MA37618A1 (fr) Dérivés pontés fluorés de spiro[2.4]heptane en tant qu'agonistes de récepteur alx
EA201790939A1 (ru) ТРИАЗОЛО[4,5-d]ПИРИМИДИНЫ В КАЧЕСТВЕ АГОНИСТОВ КАННАБИНОИДНЫХ РЕЦЕПТОРОВ ТИПА 2
MX2018013133A (es) Compuesto de pirazolo[1,5-a]pirimidina.
MA34840B1 (fr) Dérivés monoterpènes de chalcone ou de dihydrochalcone, et leur utilisation en tant qu'agents de dépigmentation
MA38679A1 (fr) Modulateurs du récepteur de cxcr7
MA40110A1 (fr) Dérivés de 7-(morpholinyl)-2-(n-pipérazinyl)méthylthiéno[2, 3-c]pyridine en tant que médicaments anticancéreux